Brief: Tempest Announces Strategic Acquisition Of New Dual-Car T Programs From Factor With Simultaneous Runway Extension Projected To Mid 2027
19/11/2025 14:08
Tempest Therapeutics Inc TPST.O: TEMPEST ANNOUNCES STRATEGIC ACQUISITION OF NEW DUAL-CAR T PROGRAMS FROM FACTOR WITH SIMULTANEOUS RUNWAY EXTENSION PROJECTED TO MID 2027 TEMPEST THERAPEUTICS INC - MATT ANGEL TO BECOME PRESIDENT AND CEO TEMPEST THERAPEUTICS INC: STEPHEN BRADY TO ASSUME ROLE OF CHAIRMAN OF BOARD UPON CLOSING OF ACQUISITION TEMPEST THERAPEUTICS INC - INVESTMENT COMMITMENT TO SUPPORT OPERATIONS TO MID 2027 TEMPEST THERAPEUTICS INC - TO ISSUE 8,268,495 SHARES TO FACTOR AFFILIATE, EQUAL TO 65% OF THE OUTSTANDING SHARES TEMPEST THERAPEUTICS INC - STOCKHOLDERS TO RECEIVE ONE WARRANT PER SHARE TEMPEST THERAPEUTICS INC: WILL HAVE GLOBAL RIGHTS TO TPST-2003 OUTSIDE OF CHINA, INDIA, TURKEY AND RUSSIA TEMPEST THERAPEUTICS INC: PLANS TO PURSUE A POTENTIAL REGISTRATIONAL STUDY IN RRMM IN U.S. STARTING IN 2027 Source text: ID:nGNX2PQR2Q Further company coverage: TPST.O
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T